Protocol-as-a-Service

Rationale

This slide demonstrates a clear, defensible business model with target unit economics. The free tier removes adoption friction, $499/mo is premium-but-justified pricing for the value delivered, and Enterprise adds GMV alignment. All economics are labeled as projections to maintain honesty at pre-revenue stage.

Talking Points

• "Our model is Protocol-as-a-Service. Three tiers, clean and simple."
• "Free Starter gets brands in the door — 1 protocol, 50 users, basic analytics. Zero risk to try."
• "Growth at $499/mo unlocks everything — unlimited protocols, unlimited users, full analytics with consumer feedback loops. This is our core revenue driver."
• "Enterprise is custom, volume-based pricing that aligns our revenue with the brand's success. The model scales with their GMV — we only earn more when they do."
• Usage-based subscription intelligence (retention moat): "Our AI companion creates a unique defensibility for the $499/mo Growth tier: usage-based subscription management. ReCharge sends on day 30 whether the customer took 30 doses or 12. We know the real consumption rate. This eliminates over-ordering — the #1 subscription cancellation reason. Brands that integrate Syntropy see subscription retention improve because the subscription finally respects the customer's actual behavior."
• "Target unit economics: $200 CAC, $5,988 twelve-month LTV. That is a projected 29.9x LTV:CAC ratio with less than one month payback."
• "Path to revenue: Y1 target is $600K ARR from 100 Growth customers. Y2 target: $2.4M as we layer in Enterprise. Y3 target: $8M as GMV revenue share kicks in."
• "For Glico specifically: the Enterprise tier is where strategic partnership becomes relevant. Imagine Glico's supplement portfolio onboarded with custom protocols — volume-based pricing aligned with your brand count, not per-seat."
• "The GTM roadmap goes beyond DTC. Phase 2 expands to B2B2C — wellness clinics, med spas, saunas like SweatHouz — where the same protocol infrastructure drives supplement commerce through their storefronts."
• "Phase 3 is licensing: white-label ShrineAI and Health Graph API access for enterprise partners who want to embed our intelligence into their own platforms."
• "Phase 4 is the strategic endgame: the Dietary Health Knowledge Graph becomes the intelligence layer for food safety and industrial applications. Every bioactive compound mapped to real-world consumer outcomes, regulatory status, and formulation compatibility. This is where precision dietary science meets industrial application."
• "The vision is NOT to be a marketing tool in a budget cage match. Each phase builds data that makes the next phase possible. DTC brands generate adherence data → that data trains the Health Graph → the Health Graph becomes the foundation for precision dietary science at industrial scale."
• Transition: "Let me introduce the team building this."

Anticipated QA

• Q: Why $499/mo? Isn't that expensive for a startup SaaS?
  A: $499/mo is less than what most DTC brands spend on a single Klaviyo email campaign. We are providing post-purchase intelligence that directly impacts retention — the most expensive problem in DTC. The ROI is clear: if we save even 5% of their churn, that is $27K+ in annual retained revenue for a $5,988 investment.
• Q: 29.9x LTV:CAC seems too good. Is the $200 CAC realistic?
  A: At scale, we expect CAC to increase to $400-600 as we move upmarket. That still yields 10-15x LTV:CAC, which is exceptional for B2B SaaS. The $200 figure reflects our current automated outreach cost structure.
• Q: How confident are you in the $600K Y1 target?
  A: 100 Growth customers in 12 months requires ~8 new customers per month. With our pipeline of 15,000 qualified companies and current engagement metrics, we need a 0.06% conversion rate. That is conservative.
• Q: How does this compare to ReCharge or Skio?
  A: ReCharge manages billing. We manage behavior. ReCharge knows when to charge; we know when to ship. That is the difference between a billing tool and an intelligence platform. ReCharge sends on day 30 regardless. We know the customer used 22 of 30 doses, so we ship on day 41. Subscriptions that match real life.
• Q: What if we wanted to invest more?
  A: We are open to discussion. A larger round accelerates Enterprise features — particularly relevant if Glico wants priority access to the platform for its portfolio brands.
• Q: Isn't Phase 4 too ambitious for a pre-seed?
  A: Phase 4 is the vision, not the ask. We're raising for Phase 1. But the architecture is designed from day one so that every protocol interaction enriches the Health Graph. We don't need to rebuild for Phase 4 — we need to accumulate data through Phases 1-3. The earlier an investor enters, the more they benefit from the compounding data asset.

Sources

• LTV calculation: $499 x 12 months = $5,988
• LTV:CAC: $5,988 / $200 = 29.94x
• Klaviyo pricing comparison: public pricing page, typical $300-800/mo for DTC brands
• Revenue projections: bottom-up model available in data room